Wild type p53 reactivation: From lab bench to clinic

被引:59
|
作者
Selivanova, Galina [1 ]
机构
[1] Karolinska Inst, Dept Microbiol Tumor & Cell Biol, SE-17177 Stockholm, Sweden
来源
FEBS LETTERS | 2014年 / 588卷 / 16期
基金
瑞典研究理事会;
关键词
p53; Small molecule; Mdm2; MdmX; Apoptosis; ROS; SMALL-MOLECULE RITA; P53-MEDIATED TUMOR SUPPRESSION; UBIQUITIN LIGASE ACTIVITY; RNA-POLYMERASE I; CANCER-THERAPY; MUTANT P53; DNA-DAMAGE; EMBRYONIC LETHALITY; MDM2; INHIBITOR; GROWTH ARREST;
D O I
10.1016/j.febslet.2014.03.049
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The p53 tumor suppressor is the most frequently inactivated gene in cancer. Several mouse models have demonstrated that the reconstitution of the p53 function suppresses the growth of established tumors. These facts, taken together, promote the idea of p53 reactivation as a strategy to combat cancer. This review will focus on recent advances in the development of small molecules which restore the function of wild type p53 by blocking its inhibitors Mdm2 and MdmX or their upstream regulators and discuss the impact of different p53 functions for tumor prevention and tumor eradication. Finally, the recent progress in p53 research will be analyzed concerning the role of p53 cofactors and cellular environment in the biological response upon p53 reactivation and how this can be applied in clinic. (C) 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
引用
下载
收藏
页码:2628 / 2638
页数:11
相关论文
共 50 条
  • [31] Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide
    Bernal, Federico
    Tyler, Andrew F.
    Korsmeyer, Stanley J.
    Walensky, Loren D.
    Verdine, Gregory L.
    Journal of the American Chemical Society, 2007, 129 (09): : 2456 - 2457
  • [32] Neurofibromatosis 1: From lab bench to clinic
    Ward, BA
    Gutmann, DH
    PEDIATRIC NEUROLOGY, 2005, 32 (04) : 221 - 228
  • [33] p53: from clinical significance to significance in the clinic?
    Hall, AR
    Braithwaite, A
    NEW ZEALAND MEDICAL JOURNAL, 1997, 110 (1052) : 347 - 348
  • [34] DOSAGE-DEPENDENT DOMINANCE OVER WILD-TYPE P53 OF A MUTANT P53 ISOLATED FROM NASOPHARYNGEAL CARCINOMA
    SUN, Y
    DONG, ZG
    NAKAMURA, K
    COLBURN, NH
    FASEB JOURNAL, 1993, 7 (10): : 944 - 950
  • [35] WILD-TYPE P53 ACTIVATES TRANSCRIPTION INVITRO
    FARMER, G
    BARGONETTI, J
    ZHU, H
    FRIEDMAN, P
    PRYWES, R
    PRIVES, C
    NATURE, 1992, 358 (6381) : 83 - 86
  • [37] Wild type p53 inhibits endothelial cell function
    Riccioni, T
    Cirielli, C
    Passaniti, A
    Capogrossi, MC
    CIRCULATION, 1996, 94 (08) : 611 - 611
  • [38] Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53
    Laurence Odin
    Marie Favrot
    Dominique Poujol
    Jean-Philippe Michot
    Philippe Moingeon
    James Tartaglia
    Isabelle Puisieux
    Cancer Gene Therapy, 2001, 8 : 87 - 98
  • [39] Effects of adenoviral wild-type p53 gene transfer in p53 -mutated lymphoma cells
    Peter Buttgereit
    Frank Schakowski
    Angela Märten
    Karsten Brand
    Sabine Renoth
    Carsten Ziske
    Björn Schöttker
    Oliver Ebert
    Roland Schroers
    Ingo GH Schmidt-Wolf
    Cancer Gene Therapy, 2001, 8 : 430 - 439
  • [40] Mitochondrially targeted wild-type p53 suppresses growth of mutant p53 lymphomas in vivo
    Palacios, G.
    Moll, U. M.
    ONCOGENE, 2006, 25 (45) : 6133 - 6139